scholarly journals Advances in the study of serum tumor markers of lung cancer

2014 ◽  
Vol 10 (7) ◽  
pp. 95 ◽  
Author(s):  
Xuechang Li ◽  
Jingbo Kang ◽  
Wenjie Qi
Cancer ◽  
1994 ◽  
Vol 73 (3) ◽  
pp. 605-609 ◽  
Author(s):  
Mitchell L. Margolis ◽  
James B. Hyzy ◽  
Larry L. Schenken ◽  
Brian S. Schepart

2021 ◽  
Vol 11 ◽  
Author(s):  
Haiqing Chen ◽  
Fangqiu Fu ◽  
Yue Zhao ◽  
Haoxuan Wu ◽  
Hong Hu ◽  
...  

ObjectivesTo assess the association between common-used serum tumor markers and recurrence of lung adenocarcinoma and squamous cell carcinoma separately and determine the prognostic value of serum tumor markers in lung adenocarcinoma featured as ground glass opacities.MethodsA total of 2,654 non-small cell lung cancer patients undergoing surgical resection between January 2008 and September 2014 were analyzed. The serum levels of carcinoma embryonic antigen (CEA), cytokeratin 19 fragment (CYFRA21-1), neuron-specific enolase (NSE), carbohydrate antigen 125 (CA125), carbohydrate antigen 153 (CA153) and carbohydrate antigen 199 (CA199) were tested preoperatively. Survival analyses were performed with COX proportional hazard regression.ResultsAmong patients with lung adenocarcinoma, elevated preoperative serum CEA(HR=1.246, 95%CI:1.043-1.488, P=0.015), CYFRA21-1(HR=1.209, 95%CI:1.015-1.441, P=0.034) and CA125(HR=1.361, 95%CI:1.053-1.757, P=0.018) were significantly associated with poorer recurrence free survival (RFS). Elevated preoperative serum CA199 predicted worse RFS in patients diagnosed with lung squamous cell carcinoma (HR=1.833, 95%CI: 1.216-2.762, P=0.004). Preoperative serum CYFRA21-1(HR=1.256, 95%CI:1.044-1.512, P=0.016) and CA125(HR=1.373, 95%CI: 1.050-1.795, P=0.020) were independent prognostic factors for patients with adenocarcinoma presenting as solid nodules while serum CEA (HR=2.160,95%CI:1.311-3.558, P=0.003) and CA125(HR=2.475,95%CI:1.163-5.266, P=0.019) were independent prognostic factors for patients with adenocarcinoma featured as ground glass opacities.ConclusionsThe prognostic significances of preoperative serum tumor markers in non-small cell lung cancer were associated with radiological features and histological types.


2022 ◽  
Vol 2022 ◽  
pp. 1-5
Author(s):  
Zhaoyin Wang ◽  
Jinbiao Huang ◽  
Minke Wang ◽  
Weixu Bi ◽  
Tianbing Fan

The number of patients with lung cancer is difficultly diagnosed in the early stage. The purpose of the study was to investigate the effects of CT- and ultrasound-guided percutaneous transthoracic needle biopsy combined with serum CA125 and CEA on the diagnosis of lung cancer. 120 patients with suspected lung cancer admitted to our hospital from January 2019 to January 2020 were selected and divided into an ultrasound group (n = 60) and CT group (n = 60), according to different percutaneous transthoracic needle biopsy modalities. All patients received serum tumor markers detection, so as to compare the CT- and ultrasound-guided percutaneous transthoracic needle biopsy results and pathology results, levels of serum tumor markers among all patients and the patients with different lung cancer types, and diagnostic efficacy of tumor markers, as well as complication rate (CR) in patients. The sensitivity and specificity of ultrasound-guided percutaneous transthoracic needle biopsy were 0.880 and 0.800, respectively, while those of CT-guided percutaneous transthoracic needle biopsy were 0.909 and 0.625, respectively; the CA125 and CEA levels in the lung cancer group were higher than those in the benign group ( P < 0.001 ); the CA125 and CEA levels of the patients with adenocarcinoma were higher than those with squamous carcinoma, and the CEA levels of the patients with small-cell carcinoma were lower than those with adenocarcinoma ( P < 0.05 ); the sensitivity, specificity, and Youden indexes of CA125 were 0.638, 0.833, and 0.471, respectively, while those of CEA were 0.766, 0.778, and 0.544, respectively; there were no significant differences in CR between the two groups ( P > 0.05 ). CT- and ultrasound-guided percutaneous transthoracic needle biopsy is a safe and feasible diagnostic modality for lung cancer, and its combination with serum CA125 and CEA can significantly improve the accuracy of the detection results, which is worthy of promotion and application in clinical practice.


2018 ◽  
Vol 1 (1) ◽  
pp. 12-17
Author(s):  
Li-Si Huang ◽  
Hai-Yan Yan ◽  
Long-Qiao-Zi Sun ◽  
Ying Xu ◽  
Dong-Hao Cai ◽  
...  

2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Derek Vos ◽  
Sanjay Rao ◽  
Jonathan D. Pierce ◽  
Daniel A. Smith ◽  
Sree Harsha Tirumani ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document